SAKAR

- Trading window to remain closed from October 1, 2026. - Closure will continue until 48 hours after the declaration of Unaudited Financial Results for the quarter ended September 30, 2026.

- Shareholders/Members of Sakar Healthcare Limited approved the appointment of M/s. Kashyap R. Mehta & Partners as Secretarial Auditors for a term of five consecutive years. They will conduct the Secretarial Audit for financial years FY 2026-27 to FY 2030-31. The approval was granted in the 22nd Annual General Meeting held on 22nd September, 2026.

- Sakar Healthcare Ltd. will hold a group meeting with analysts/investors on September 17th & 18th, 2026. - The meeting will be in-person, involving a plant visit and management interaction. - No unpublished price-sensitive information will be shared.

- Investor Meeting Schedule - Meeting Date: September 17th & 18th, 2026 - Meeting Type: In-person Plant Visit and Management interaction with analysts and investors

- Sakar Healthcare Ltd. received 14 new oncology product approvals in the EU, UK & Canada with 7 business partners. - 6 of Sakar's licensed out products were granted Marketing Authorizations (4 in EU, 1 in UK, 1 in Canada). - These approvals enhance market coverage for various cancer types and are expected to drive top-line sales.